<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690231</url>
  </required_header>
  <id_info>
    <org_study_id>PKUPH-sarcoma 14</org_study_id>
    <nct_id>NCT04690231</nct_id>
  </id_info>
  <brief_title>Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma</brief_title>
  <official_title>Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shougang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic&#xD;
      polychemotherapy followed by local surgical therapy and then postoperative (adjuvant)&#xD;
      chemotherapy, long-term, disease-free survival can be achieved in 60- 70% of osteosarcoma&#xD;
      patients. However treatment options for osteosarcomas, especially in the setting of&#xD;
      metastatic or unresectable disease, are very scarce. Apatinib has been proved to be an&#xD;
      effective agent to prolong progression-free survival in advanced osteosarcoma. But after 4-6&#xD;
      months' treatment, secondary resistance always occurred with musculoskeletal lesions'&#xD;
      progression or new metastasis.&#xD;
&#xD;
      Nowadays giving therapeutic doses of IE concurrently with anti-angiogenesis tyrosine kinase&#xD;
      inhibitors is a conceptually attractive strategy for treating patients with refractory&#xD;
      osteosarcoma according to prospective trial of lenvatinib +IE reported by Gaspar et al at&#xD;
      2019 ESMO and 2020 ESMO. Thus This study was designed to review our experience in real world&#xD;
      for off-label use and characterize the toxicity profile of concurrent apatinib+IE and IE&#xD;
      alone in patients with relapsed or refractory osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>from start treatment to any events/death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>from start treatment to progression/death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>from start treatment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Effect of Drug</condition>
  <condition>Toxicity, Drug</condition>
  <condition>Secondary Resistance</condition>
  <arm_group>
    <arm_group_label>Apatinib+IE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3</description>
    <arm_group_label>Apatinib+IE</arm_group_label>
    <other_name>ifosfamide and etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide and etoposide</intervention_name>
    <description>ifosfamide and etoposide</description>
    <arm_group_label>Apatinib+IE</arm_group_label>
    <arm_group_label>IE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histological diagnosis of osteosarcoma (confirmed by central pathological review by an&#xD;
             expert pathologist from the Peking University People's Hospital)&#xD;
&#xD;
          -  objective disease progression within 3 months prior to treatment according to RECIST&#xD;
             1.1&#xD;
&#xD;
          -  previously treated with one to two lines of chemotherapy for metastatic disease&#xD;
&#xD;
          -  have an adequate performance status (adults:Eastern Cooperative Oncology Group [ECOG]&#xD;
             performance status of 0-1;children aged &gt;12 years: a score of ≥60% on the Karnofsky&#xD;
             performance scale; children aged ≤12 years a score of ≥60% on the Lansky scale)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  a life expectancy of less than 3 months&#xD;
&#xD;
          -  patients had to have adequate bone marrow function, normal renal function, normal&#xD;
             liver function, and normal pancreatic function&#xD;
&#xD;
          -  no other malignant tumors&#xD;
&#xD;
          -  no malignant pleural and peritoneal effusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xie L, Xu J, Sun X, Tang X, Yan T, Yang R, Guo W. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial. Oncologist. 2019 Jul;24(7):e542-e550. doi: 10.1634/theoncologist.2018-0542. Epub 2018 Dec 17.</citation>
    <PMID>30559126</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 26, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>March 28, 2021</last_update_submitted>
  <last_update_submitted_qc>March 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteosarcoma</keyword>
  <keyword>apatinib</keyword>
  <keyword>ifosfamide and etoposide</keyword>
  <keyword>prognosis</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

